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reduced BMD in both trabecular and cortical bone. This reduc-Bone loss in long-term renal transplantation: Histopathology
tion in BMD was not as severe as in short-term reports and wasand densitometry analysis.
associated with osteoclast stimulation, osteoblast suppression,Background. There is little information of the spectrum and
and retardation of mineral apposition and bone formationfactors implicated in the bone loss in long-term renal trans-
rates. Bone mass loss was not different between the immuno-plantation, and virtually no data using both histomorphometric
suppression therapy groups. Male gender and age were theand densitometric analysis.
strongest predictive factors for low bone mass.Methods. Twenty-three males and 22 females (13 postmeno-
pausal) were studied with a bone biopsy and densitometry.
Sixteen patients were on cyclosporine A monotherapy, 20 on
azathioprine 1 prednisolone, and 9 on cyclosporine A 1 pred-
Disorders of mineral and bone metabolism have annisolone or triple therapy. The mean time after transplantation
impact on significant morbidity in patients with end-was 127 6 70 months.
Results. No group had a significant decrease in bone mineral stage renal disease, and play a prominent role in the
density (BMD) of the axial skeleton compared with an age- and development of renal osteodystrophy [1, 2]. Kidney
sex-matched normal population. Compared with sex-matched transplantation improves the metabolic environment andyoung controls, osteopenia was observed in all groups at the
restores the glomerular filtration and renal production offemoral neck (except premenopausal women and triple ther-
1,25-dihydroxyvitamin D3 impaired during chronic renalapy) and in the triple-therapy group at the L1–L4 spine region.
At the distal radius, osteopenia was found in all the groups. failure. In spite of this, patients with kidney transplanta-
Histopathological diagnosis was mixed uremic osteodystrophy tion, as well as heart and liver transplant recipients, have
in 46.5%, adynamic bone in 23.2%, hyperparathyroid disease been shown to be at risk for bone loss [3–6]. Osteopenia,in 13.9%, and normal bone in 16.3%. The diagnosis was not
avascular bone necrosis, fractures, and persisting hyper-different according to immunosuppressive therapy, but men
tended to show more mixed uremic bone disease. There was parathyroid bone disease are common after transplanta-
no significant difference in BMD between histopathological tion [3, 4, 7]. It has repeatedly been demonstrated that
subtypes. In general, patients showed slight osteoclast function bone loss is highest within the first 6 to 18 months after
increase, osteoblast function decrease, and marked retardation
renal transplantation [8–10]. Cross-sectional data suggestof dynamic parameters. The cyclosporine A monotherapy
that beyond three years after transplantation, the bonegroup had a significantly lower appositional rate than azathio-
prine 1 prednisolone. Men had a significantly lower bone vol- mineral density (BMD) does not change or might in-
ume than women, and premenopausal women had a signifi- crease slightly, but remains below the normal population
cantly lower mineralizing surface than postmenopausal women reference values [11]. Others, however, have suggested
and men. In the multivariate analysis, male gender, time after
that a continuous demineralization process is present intransplantation, old age, and time on dialysis prior to trans-
long-term renal transplant recipients [12].plantation were significant predictive factors for a negative
effect on bone mass. Before the introduction of cyclosporine A (CsA) as
Conclusions. Long-term renal transplant patients showed an immunosuppressive agent, bone loss following trans-
plantation was attributed primarily to glucocorticoids
[13, 14]. As CsA reduces the requirements for glucocorti-Key words: bone mineral density, cyclosporine A, glucocorticoids, os-
teoclast, osteoblast, immunosuppression, renal osteodystrophy. coids, an improvement of the bone loss in the post-
transplant period was expected with its wide use. How-Received for publication June 5, 1998
ever, this expectation has not been fulfilled, as boneand in revised form December 21, 1998
Accepted for publication December 22, 1998 alterations remain a problem [8–10, 15–20]. In humans,
several immunosuppressive regimens, including CsA and 1999 by the International Society of Nephrology
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prednisolone (PRED), have been shown to decrease suppressive therapy received. In our renal unit, immuno-
suppression protocols were as follows.lumbar BMD [8–10, 18–20]. Moreover, conflicting results
CsA monotherapy. CsA was infused intravenously athave been reported about the role of age, sex, postmeno-
a dosage of 5 mg/kg at days 0 and 1, continued orallypausal status, type and duration of dialysis treatment,
at a dose of 15 mg/kg/day, and progressively reducedimmunosuppressive therapy, graft rejection episodes,
according with serum CsA levels (100 to 150 pg/ml).persistent hyperparathyroidism, and decreased creati-
Azathioprine (AZA) 1 PRED dual therapy. PREDnine clearance as risk factors for the bone loss related
20 mg/day was given orally for the first 90 days and thento kidney transplantation [10, 11, 18–20].
reduced monthly to a maintenance dose of 5 to 10 mg/Mineralized bone histopathology provides the best in-
day. AZA was started at 2 mg/kg/day and then progres-formation regarding bone abnormalities; however, this
sively decreased to a maintenance dose of 1 mg/kg/day.technique is underused because of perceived constraints
Triple therapy (CsA 1 AZA 1 PRED). After the[21]. There is scarce histopathological information on
CsA intravenous infusion of the first two days, this drugthe bone loss associated with short-term renal trans-
was given orally at a dose of 15 mg/kg/day and thenplantation and virtually no data on long-term adult renal
tapered off to a maintenance dose of 5 mg/kg/day (ac-recipients. Recently, one study performed in children
cordingly with serum levels). AZA and PRED wereand adolescents (employing histopathological and bone
given as before.mineral content analysis) suggests that reductions in
Rejection episodes were treated with three daily intra-bone mass and post-transplant osteoporosis are not
venous methylprednisolone boluses (1.0 g each). Intrave-prominent findings in this renal transplant population
nous monoclonal antibodies against T-lymphocyteswhen the influence of growth retardation on bone mass
(OKT3) or anti-thymocyte globulin (ATG) was given inis carefully considered [22]. In adults, to the best of our
case of steroid-resistant rejection. Cumulative doses ofknowledge, no study has been undertaken in the long-
CsA, PRED, and AZA were calculated, consideringterm setting, employing both histomorphometry and
both intravenous and oral doses. Methylprednisolonedensitometry analysis. Therefore, our cross-sectional
and PRED were considered as equipotent.study was designed, employing bone histomorphometry
Twelve patients were changed from one immunosup-and densitometry, to investigate the spectrum of the
pressive group to another: eight patients from CsAbone disease in adult patients with long-term, successful
monotherapy transferred to conventional, CsA 1 PRED,renal transplantation. The association between these his-
or triple-therapy group because of repeated rejectiontomorphometric and densitometric parameters with
episodes, and four patients from the triple therapy to asome biochemical, clinical, and immunosuppression vari-
dual or monotherapy group to decrease side-effects. All
ables was also analyzed. patients were receiving their final immunosuppressive
therapy (as classified in this study) for at least two years
prior to the study. PRED and CsA have been consideredMETHODS
the most relevant drugs for bone loss after transplanta-Patients
tion; thus, patients on triple immunosuppression and on
Forty-five patients were studied: 23 male and 22 female CsA 1 PRED were considered as one group.
(13 postmenopausal; time since menopause 11.2 6 8.3
years). The mean age was 48 6 12 years, and the time Bone histological evaluation
after transplantation was 127 6 70 months. The cause After double tetracycline labeling, bone biopsies were
of renal failure was chronic primary glomerulonephritis taken from the anterior iliac crest using an 8 mm Bordier
in 18, reflux nephropathy in 8, adult polycystic kidney trephine biopsy needle as described previously [23].
disease in 7, unknown in 4, obstructive nephropathy in Specimens were processed as described in detail else-
3, diabetes mellitus in 2, and other cause in 3. Only four where [24] and were analyzed by a single pathologist
patients were on furosemide, with a mean cumulative (A.J.F.), who was blinded to patients’ details. Bone histo-
dose of 262 6 225 g. Patients were selected randomly if morphometry was performed according to guidelines of
they had a first kidney transplant performed over two the ASBMR histomorphometry nomenclature commit-
years previously, had stable graft function (serum creati- tee [25]. Results were compared with age- and sex-
nine of less than 180 mmol/liter), and gave informed matched normal values (Z scores) derived from the
consent. Exclusion criteria included any condition (pro- database biopsies for 234 normal subjects (including 84
longed immobilization, systemic illness, or malignancy) individuals with double tetracycline labeling) and nec-
or intake of drugs (other than immunosuppression) that ropsies currently employed in our department [24].
could affect bone metabolism. No patient received cal-
Bone mineral density measurementscium carbonate or calcitriol after transplantation.
Patients were classified into groups according to gen- Within two weeks of the bone biopsy, BMD of the
axial and appendicular skeleton was determined by den-der and menopausal status and according to the immuno-
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sitometry. BMD of the forearm (distal radius) was ana- sidered independent variables. Collinearity between in-
dependent variables was tested by Durbin–Watson test.lyzed by single-energy x-ray absorptiometry (SXA) using
a bone densitometer DTX-100 (Osteometer; MediTech, A two-tail P , 0.05 was accepted as significant, but the
exact value is preferentially shown.Roedrove, Denmark). The density of the right femoral
neck and lumbar spine (L1–L4) was evaluated by dual-
energy x-ray absorptiometry (DXA) using a DPX scan-
RESULTS
ner (Lunar Corporation, Madison, WI, USA). Results
At the time of the study, 16 patients were on CsAwere compared with values of age- and sex-matched
monotherapy, 20 on AZA 1 PRED, 6 on CsA 1 PRED,reference population (Z score) and with values of sex-
and 3 on triple therapy. One patient had a history of hipmatched peak bone mass of a young control population
replacement (avascular necrosis). Two had a history of(T score) currently employed in the Department of Diag-
peripheral bone fracture. Three had vertebral disc spacenostic Radiology, University of Manchester. Densitome-
narrowing. One had chronic knee bone pain. Two hadters were calibrated every morning against a phantom
generalized bone pain, and one had loss of the hip jointprovided by dealers. The SXA densitometer was autocal-
space and sclerosis. Relevant clinical information ac-ibrated using an integrated computer program. In the
cording to the immunosuppressive therapy and sex iscase of the DXA densitometer, the coefficient of variabil-
shown in Table 1. The time after transplantation wasity for femoral neck was 2.07% and 1.57% for L1–L4.
significantly longer in the AZA 1 PRED group than
in the other two immunosuppressive groups, probablyLaboratory tests
because this scheme was the first employed in our renalBlood samples were obtained on the day of the bone
unit but has been subjected to a restricted use in thebiopsy. Ionized calcium, phosphate, and creatinine were
last five years. A cumulative dose of PRED in the CsAmeasured by standard techniques. Bone specific alkaline
monotherapy group represents only steroids given dur-phosphatase was assayed by colorimetry and carboxyter-
ing graft rejection episodes.minal telopeptide of type I collagen and propeptide of
Detailed biochemical characteristics are shown in Ta-type I procollagen by radioimmunoassay. Intact mole-
ble 2. The mean propeptide of type I procollagen wascule of parathyroid hormone (iPTH) was measured by
higher in premenopausal and postmenopausal womenimmunoradiometric assay (Nichols Institute Diagnostics,
than reference values for women (50 to 170 mg/liter).San Juan Capistrano, CA, USA), and 1,25-dihydroxyvi-
All groups showed a mean telopeptide of type I collagentamin D3 was evaluated by radioimmunoassay on a 1217
higher than reference values (1.6 to 4.6 mg/liter).Rackbeta Scintillation Spectrometer (Crownhill Wal-
Table 3 shows the bone densitometry data. Comparedlac, UK).
with an age- and sex-matched normal population (Z
Statistical analysis score), no group had a significant reduction of BMD at
L1–L4 and femoral neck, and none was in the range forResults are shown as mean 6 sd. Comparisons of
fracture risk [26]. However, when compared with thedimensional variables between two groups were per-
peak bone mass of sex-matched young normal controlsformed by the independent samples t-test or Mann–
(T score), osteopenia (according to the World HealthWhitney U-test as appropriate and between three groups
Organization diagnostic criteria) [27] was observed atby analysis of variance. In case of a significant model
the femoral neck in all groups except premenopausalobtained in the latter analysis, all pair-wise multiple com-
women and patients on triple therapy. In the appendicu-parisons were analyzed by the Student–Newman–Keuls
lar skeleton, a greater reduction of BMD was evident asmethod. A comparison of nominal variables was per-
osteopenia was found in all the groups at the distal radius.formed by x2 or Fisher’s exact test as appropriate. Uni-
No significant differences of BMD measurements be-variate association analysis was done by Pearson’s or
tween groups according to immunosuppressive drugSpearman’s correlation coefficients (as appropriate).
therapy, gender, or menopausal status were observed.Multivariate analysis was carried out by stepwise multi-
However, men seemed to display BMD T scores as de-ple linear regression. All of the univariate and multivari-
creased as postmenopausal women and lower than pre-ate analyses, in which densitometric and histomorpho-
menopausal women (although this difference was notmetric parameters were regarded as dependent variables,
statistically significant).were performed considering Z scores. We consider these
Two bone biopsy samples were not useful for histo-scores as the best way to control for the influence of age
pathological diagnosis. In the remaining 43 patients, theand gender, which are known risk factors for bone loss
histopathological analysis revealed mixed uremic bonein the normal population [24, 26]. Age, sex, creatinine
disease in 20 (46.5%) patients, adynamic bone in 10clearance, iPTH, rejection episodes, type and time on
(23.2%), hyperparathyroid bone disease in 6 (13.9%),dialysis before transplantation, time after transplanta-
tion, and cumulative dose of PRED and CsA were con- and normal bone in 7 (16.3%). Histopathological diagno-
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Table 1. Clinical characteristics according immunosuppression therapy, sex and menopausal status
Immunosuppression therapy Sex
CsA mono AZA 1 PRED Triple Premenopausal Postmenopausal Male
Clinical (N 5 16) (N 5 20) (N 5 9) Female (N 5 9) Female (N 5 13) (N 5 23)
Premenopausal/postmenopausal/men 3/5/8 4/5/11 2/3/4
Age years 50.6612.1 48.3 611.2 42.2613.2 34.9 67.0c 57.565.9d 47.6611.4
Weight kg 73.7618.6 73.9 613.9 66.967.3 73.1 618.7 65.9610.3 75.2 614.8
Type of dialysis before the graft
Nil/HD/PD (N) 4/3/9 6/10/4 1/3/5 1/4/4 4/3/6 6/9/8
Time on dialysis months 17.4624.1 9.1 611.4 12.368.3 19.9 622.3 15.5622.7 8.3 67.2
Time since transplantation months 80630 186659a 78636 117670 114664 138 675
Rejection episodes 0.5060.63 1.00 61.08 1.2261.20 1.33 61.0 0.9261.04 0.65 60.93
Cumulated dose of CsA g 7256274 70 6141a 7016387 418 63986 4486414 423 6431
Cumulated dose of PRED g 2.163.4b 43.8612.4 35.4647.7 25.1 621.2 30.8643.5 26.2 622.3
Abbreviations are: CsA, cyclosporine A; AZA, azathioprine; PRED, prednisolone; HD, hemodialysis; PD, peritoneal dialysis; CD, cadaveric donor; LRD, living
related donor.
a P , 0.05 vs. CsA monotherapy
b P , 0.05 vs. AZA 1 PRED and triple therapy groups
c P , 0.05 vs. postmenopausal female and male
d P , 0.05 vs. male
Table 2. Biochemical characteristics according immunosuppression therapy, sex and menopausal status
Immunosuppression therapy Sex
CsA mono AZA 1 PRED Triple Premenopausal Postmenopausal Male
Biochemical variable (N 5 16) (N 5 20) (N 5 9) Female (N 5 9) Female (N 5 13) (N 5 23)
iPTH pg/ml 85.0645.1 69.0640.2 65.2 635.0 64.8632.3 90.1 640.1 68.3643.4
Ionised calcium mmol/liter 1.2660.07 1.2560.07 1.24 60.03 1.2260.08 1.26 60.04 1.2660.06
Phosphate mmol/liter 0.9060.18 0.8560.21 0.92 60.25 0.8860.25 0.92 60.21 0.8560.19
Telopeptide of Type I collagen lg/liter 8.363.0a 5.963.0 8.9 64.2 8.463.9 7.2 63.7 7.063.2
Propeptide of Type I collagen lg/liter 182679 173690 196 692 202684 185 6104 169676
1,25-Dihydroxyvitamin D3 pg/ml 32.668.3 35.1615.1 32.0 615.0 29.469.2 31.2 611.8 36.5614.2
Bone alkaline phosphatase U/liter 39.1622.4 35.5624.9 38.9 621.0 36.4627.5 39.1 630.5 36.9616.1
Creatinine lmol/liter 133623 118622 135 623 129625 124 621 127625
Creatinine clearance ml/min 50.7610.3a 68.4622.2 55.3 613.0 62.7623.5 47.0 612.2b 67.3617.4
a P , 0.05 vs. AZA 1 PRED group
b P , 0.05 vs. Male
Table 3. Bone densitometry data according the immunosuppression therapy, sex and menopausal status
Immunosuppression therapy Sex
CsA mono AZA 1 PRED Triple Premenopausal Postmenopausal Male
Densitometric variable (N 5 16) (N 5 20) (N 5 9) Female (N 5 9) Female (N 5 13) (N 5 23)
Single energy X-ray absorptiometry
Distal
Z score 20.860.8 21.061.0 21.161.1 21.060.7 20.660.9 21.161.0
T score 21.761.1 21.961.1 21.761.3 21.060.7 21.961.2 22.061.1
Dual energy X-ray absorptiometry
Femoral neck
Z score 20.760.9 20.561.1 20.561.2 20.761.3 20.261.1 20.760.9
T score 21.461.2 21.161.1 21.061.3 20.661.3 21.361.4 21.460.9
L1-L4
Z score 0.3 61.2 20.261.4 20.861.5 20.561.2 0.4 61.6 20.461.3
T score 20.461.3 20.861.4 21.361.4 20.561.1 20.861.8 20.961.3
sis according to immunosuppressive drug therapy was only one case (diagnosed as adynamic bone disease),
aluminum was present in bone, cement lines and dif-not different (Fig. 1A). Men tended to show a higher
proportion of mixed uremic bone disease than women fusely (not restricted to the mineralizing front); this was
considered to be biologically inactive. Iron was not ob-(Fig. 1B). Bone marrow was normal in 24 cases. In 17,
there was mild fibrosis and moderate fibrosis in 2. In served in any biopsy. A trend to a better preserved BMD
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order to identify the effect of CsA clearly, we decided
to remove the data of those patients with an iPTH higher
than the reference values (10 to 60 pg/ml). This also
removed those patients with the lowest creatinine clear-
ance, as the latter was negatively correlated with iPTH
(r 5 –0.40, P 5 0.01). There were 24 patients with iPTH
levels higher than 60 pg/ml: 98.0 6 29.1 pg/ml (range 63
to 168). A new analysis was performed in 21 patients
with normal PTH who were on CsA monotherapy
(N 5 6), AZA 1 PRED (N 5 9), and triple therapy
(N 5 6). Figure 2 shows the main significant results of
this further analysis. CsA monotherapy was associated
with a significantly more pronounced reduction in wall
thickness compared with the AZA 1 PRED and triple-
therapy groups and in trabecular appositional rate
compared with the AZA 1 PRED group. In this same
analysis, males showed a lower bone volume than post-
menopausal women (Fig. 2).
As in any clinical conditions in which multiple vari-
ables interact at the same time in a given patient, renal
transplant bone mass reduction has a multifactorial ori-
gin. To identify clearly which factor(s) was indepen-
dently associated with the bone mass reduction in our
study, we performed a multiple regression analysis once
collinearity between the independent variables was ex-
cluded. Table 6 shows only the significant models
obtained in this multivariate analysis. There was no sig-
nificant model predicting BMD. Regarding the histo-
morphometric variables, sex (female 0, male 1) and timeFig. 1. Histopathological diagnosis according to the immunosuppres-
sion drug therapy (A) and gender and menopausal status (B). Symbols after transplantation were the most significant factors
are: ( ) predominant hyperparathyroid bone disease; ( ) adynamic predicting bone volume and mineralizing surface,
bone disease; ( ) mixed uremic bone disease; ( ) normal bone.
whereas age and time on dialysis prior to the transplanta-
tion were the only significant predictive factors for
eroded surface and osteoclast number, respectively.
was observed in patients with normal bone histology
(mainly at the L1–L4 level); however, there were no
DISCUSSIONsignificant differences between the histopathological
This study showed a mild to moderate BMD reductionsubtypes (Table 4). Detailed results of the histomorpho-
in both axial and appendicular skeleton of patients withmetric analysis are shown in Table 5. In general, patients
long-term renal transplantation, which was not signifi-showed a slight to moderate increase in osteoclast func-
cantly different in patients receiving CsA alone, AZA 1tion and a decrease of osteoblast function, as well as
PRED, or triple therapy. Although there was a trenda marked retardation of mineral apposition and bone
to display a lower BMD compared with age- and sex-formation rates. There was a wide variance in all of the
matched normal population or with sex-matched younghistomorphometric parameters; however, some differ-
controls, the lumbar spine seemed to be less affected.ences were found. Adjusted for age and sex, patients on
The magnitude of reduction in the axial skeleton BMDCsA monotherapy had a lower appositional rate com-
in our study is in keeping with that reported by Grotzpared with the AZA 1 PRED group, and men displayed
et al [11], but contrasts with the severe demineralizationlower bone volume than premenopausal and postmeno-
of the spine reported by Pichette et al in long-term kid-pausal women, whereas premenopausal women had a
ney transplant survivors [12]. Our results in the distallower mineralizing surface than postmenopausal women
radius BMD (predominantly cortical bone) also contrastand men.
with those reported by Julian et al in the short termThe CsA monotherapy and premenopausal women
after transplantation, as they found an increase in BMDgroups showed a trend toward higher serum iPTH and
probably caused by resolution of mild secondary hyper-significantly lower creatinine clearance values. Although
the serum iPTH levels were not particularly high, in parathyroidism [8]. The BMD reduction in our patients
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Table 4. Comparison of bone mineral density (BMD) measurements between the different histopathological subtypes
Densitometric variable Normal (N 5 7) Mixed (N 5 20) HPT (N 5 6) Adynamic (N 5 10)
Single energy X-ray absorptiometry
Distal
Z score 20.761.0 20.960.9 21.261.1 21.260.8
T score 21.460.7 21.961.2 21.861.5 21.960.9
Dual energy X-ray absorptiometry
Femoral neck
Z score 20.561.2 20.561.2 20.360.5 20.860.9
T score 21.161.1 21.461.3 20.960.7 21.361.2
L1-L4
Z score 0.861.3 20.361.4 20.360.8 20.461.7
T score 0.161.3 21.061.4 20.861.1 20.861.6
Abbreviations are: Normal, normal bone; Mixed, mixed uremic bone disease; HPT, predominant hyperparathyroid bone disease; Adynamic, adynamic bone.
Table 5. Histomorphometric analysis according immunosuppression therapy, sex and menopausal status
Immunosuppression therapy Sex
Histomorphometric variable CsA mono AZA 1 PRED Triple Premenopausal Postmenopausal Male
(trabecular bone) (N 5 16) (N 5 19) (N 5 8) Female (N 5 9) Female (N 5 13) (N 5 21)
Z score
Bone volume 21.661.8 22.662.0 21.960.8 21.161.5 21.661.3 22.861.9c
Osteoblast surface 20.966.4 21.564.7 22.762.0 21.865.2 21.164.0 21.665.7
Osteoid surface 21.263.8 22.263.2 22.862.8 22.863.4 21.763.3 21.763.5
Wall thickness 24.265.7 23.963.1 22.561.6 23.062.4 22.562.6 24.865.1
Osteoclast number 1.764.3 1.863.4 0.9 62.6 20.0263.4 2.3 62.8 1.864.0
Osteoclast surface 3.5611.2 1.763.3 2.2 62.9 3.5615.0 2.2 62.5 2.263.7
Eroded surface 1.366.1 2.264.4 4.9 68.8 0.665.6 2.0 62.8 3.467.4
Mineralizing surface 25.665.3 27.169.9 24.363.5 211.8612.6b 23.463.7 25.264.9
Bone formation rate 24.464.1 25.6616.1 22.962.0 23.465.6 23.663.6 25.8615.1
Appositional rate 26.562.7a 24.463.2 24.262.4 26.062.7 24.162.5 25.563.4
a P , 0.05 vs. AZA 1 PRED
b P , 0.05 vs. female postmenopausal and male
c P , 0.05 vs. female pre- and postmenopausal
could theoretically be related to hyperparathyroidism, another study, a higher frequency of non–aluminum-
related adynamic bone disease was reported in a Mexi-but we did not find any correlation between PTH and
distal radius BMD. Alternatively, a technical difference can population after 84 months of transplantation [29];
however, a discriminative analysis of the associated fac-could be implicated, as we used SXA, which has better
spatial resolution (and therefore, enhanced precision) tors was not performed. In our study, the most frequent
histopathological diagnosis was mixed uremic bone dis-than single-photon absorptiometry [28] as employed by
Julian et al [8]. ease. Interesting to note is the lack of differences in
BMD between the histopathological subtypes, evenOur bone histopathological findings of an imbalance in
bone remodeling favoring net bone loss, that is, increased when patients with normal bone tended to show a slightly
better BMD. This may suggest that even patients withosteoclast function, decreased osteoblast function, and
retardation of mineral apposition, and bone formation adynamic bone suffer from bone demineralization.
Bone loss and fracture rates after renal transplantationrates clearly explain the densitometry data. Few studies
have addressed the histopathological picture in patients may be lower than after liver [5] or cardiac [6] trans-
plantation, probably because lower doses of immunosup-receiving combined regimens of CsA and PRED in short-
term renal transplantation. The histomorphometric fea- pressive drugs are used [30]. Nevertheless, a triple frac-
ture rate after renal transplantation has been reportedtures displayed in our study population have been de-
scribed previously in bone biopsies after six months of that is related to low lumbar BMD [7]. The long bones
appear to be more commonly affected than the vertebraltransplantation and were attributed to a toxic effect of
glucocorticoids [8]. Others have found increased osteo- bodies in kidney transplant recipients [7, 30], as was the
case in this study.clast and osteoblast activity one- to two-years post-trans-
plantation, attributing these effects to delayed bone re- In humans, the study of the role of different immuno-
suppressive drugs has produced contradictory results.pair due to CsA [16] or resistance of bone to normal
circulating levels of 1,25-dihydroxyvitamin D3 [17]. In Some authors have suggested PRED as the main factor
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Table 6. Significant multiple linear regression models predicting
histomorphometric parameters (only significant independent
variables are shown)
Dependent variable Independent variables b P
Bone volume Sex 20.36 0.01
R 0.54, R2 0.30, P 5 0.002 Time after transplantation 20.36 0.02
Eroded surface Age 0.36 0.03
R 0.36, R2 0.13, P 5 0.03
Osteoclast number Time on dialysis 20.38 0.02
R 0.38, R2 0.14, P 5 0.02
Mineralizing surface Time after transplantation 20.40 0.01
R 0.50, R2 0.25, P 5 0.006 Sex 0.37 0.02
Independent variables included: age, sex (female 0, male 1), creatinine clear-
ance, iPTH, rejection episodes, type and time on dialysis before transplantation,
time after transplantation, and cumulative dose of PRED, CsA, and AZA.
of the immunosuppressive drug schemes were associated
with bone loss to roughly the same degree. High serum
PTH levels have been implicated in bone loss related to
renal transplantation whether as persistent hyperpara-
thyroidism [10] or secondarily related to the develop-
ment of mild to moderate renal failure [17]. As our group
on CsA monotherapy showed a slightly higher iPTH and
lower creatinine clearance, it could be speculated that
the observed effects were due to secondary hyperpara-
thyroidism. In a further analysis, eliminating those pa-
tients with an iPTH level above the normal range (hence,
eliminating the patients with the poorest renal function),
the negative effect of CsA monotherapy on the trabecu-
lar appositional rate and wall thickness were still evident.
In addition, no correlation between PTH levels and the
histomorphometric parameters was observed. Likewise,
the trabecular bone loss and imbalance of bone forma-
tion and resorption observed in our patients are not
usually present in the PTH excess [36, 37]. Thus, the
histomorphometric picture observed in our patients does
not seem to be explained by PTH alone. The low levels
of bone specific alkaline phosphatase (reference valuesFig. 2. The Z score of trabecular appositional rate, wall thickness, and
bone volume in 21 patients with normal PTH level, according to the 30 to 150 U/liter) displayed in this study agree with the
immunosuppressive therapy (A and B) and gender (C). *P , 0.05 vs. general osteoblast hypoactivity observed. The higher se-
CsA monotherapy.
rum levels of telopeptide of type I collagen in the CsA
monotherapy group suggest higher resorption; however,
this might have been affected by the poorer renal func-
tion in this group, as it has been reported that creatinineimplicated in BMD loss after renal transplantation [11,
12, 20]. Others have claimed a positive impact of CsA clearance below 75 ml/min increases the serum concen-
tration of this small peptide [38]. This is supported byon the lumbar BMD [19, 20]. Nevertheless, CsA may be
related to bone loss because, in in vivo animal studies, a negative correlation between serum concentration of
telopeptide of type I collagen and creatinine clearanceCsA causes high-turnover osteopenia with trabecular
bone loss and a transient rise in serum osteocalcin [31, (r 5 –0.37, P 5 0.02).
Age, sex, and postmenopausal status are factors affect-32] and 1,25-dihydroxyvitamin D3 [32], whereas in vitro,
CsA inhibits bone resorption elicited by calcemic hor- ing natural bone loss in the normal population [24, 26],
but their role in renal transplantation remains controver-mones or cytokines [33, 34] and fusion of osteoclast pre-
cursors [35]. Our data show that in the long term, PRED, sial. Our data show a trend for postmenopausal women
to exhibit a lower BMD than premenopausal womenas well as CsA alone or triple-drug therapy, is associated
with osteoclast activation, osteoblast suppression, and when compared with a sex-matched young population.
However, when compared with age- and sex-matchedretardation of bone formation parameters. Moreover, all
Cueto-Manzano et al: Bone loss in long-term renal transplantation2028
9. Horber FF, Casez JP, Steiger U, Czeerniak A, Montandon A,peers, premenopausal women tended to have lower
Jaeger PD: Changes in bone mass early after kidney transplanta-
BMD. Furthermore, men tended to have low BMD, as tion. J Bone Miner Res 9:1–9, 1994
10. Almond MK, Kwan JTC, Evans K, Cunningham J: Loss of re-well as bone volume significantly lower than postmeno-
gional bone mineral density in the first 12 months following renalpausal women. Consequently, it was expected that male
transplantation. Nephron 66:52–57, 1994
gender is a negative predictive factor for bone volume, 11. Grotz WH, Mundinger FA, Rasenack J, Speidel L, Olschewski
M, Exner VM, Schollmeyer PJ: Bone loss after kidney trans-and its association with a low BMD seems clear in this
plantation: A longitudinal study in 115 graft recipients. Nephrolsetting. Age predicted a higher eroded surface, which
Dial Transplant 10:2096–2100, 1995
may be considered as exceeding its natural effect, as 12. Pichette V, Bonnardeaux A, Prudhomme L, Gagne´ M, Car-
dicnal J, Ouimet D: Long-term bone loss in kidney transplantthis effect was observed employing Z scores. Time after
recipients: A cross-sectional and longitudinal study. Am J Kidneytransplantation negatively predicted trabecular bone
Dis 28:105–111, 1996
volume; therefore, its main implication is that reduced 13. Slatopolsky E, Martin K: Glucocorticoids and renal transplant
osteonecrosis. Adv Exp Med Biol 171:353–359, 1984bone mass is still present in long-term renal transplanta-
14. Luckert BP, Raisz LG: Glucocorticoid-induced osteoporosis:tion.
Pathogenesis and management. Ann Intern Med 112:352–364, 1990
In summary, long-term renal transplant patients 15. Epstein S: Cyclosporin A: Friend or foe? Calcif Tissue Int 49:232–
234, 1991showed reduced BMD in both trabecular and cortical
16. Aubia J, Masramo´n J, Serrano S, Lloveras J, Marin˜oso LL:bone. This reduction in BMD was not as severe as has
Bone histology in renal transplant patients receiving cyclosporin.
been reported in short-term studies and appears to result Lancet 1:1048-1049, 1988
17. Briner VA, Thiel G, Monier-Faugere MC, Bognar B, Land-from an imbalance in bone remodeling, characterized,
mann J, Kamber V, Malluche HH: Prevention of cancellous bonein turn, by osteoclast stimulation, osteoblast suppression,
loss but persistence of renal bone disease despite normal 1,25
and retardation of mineral apposition and bone forma- vitamin D levels two years after kidney transplantation. Trans-
plantation 10:1393–1400, 1995tion rates. Bone mass loss was not different between
18. Wolpaw T, Deal CL, Fleming-Brooks S, Bartucci MR, Schulakthe CsA monotherapy, AZA 1 PRED dual therapy, or
J, Hricik DE: Factors influencing vertebral bone density after renal
triple immunosuppressive therapy groups. Male gender transplantation. Transplantation 58:1186–1189, 1994
19. Torregrosa JV, Campistol JM, Montesinos M, Pons M, Marinesand age were the strongest predictive factors for a nega-
de Osaba MJ: Evolution of bone mineral density after renal trans-tive outcome on bone mass.
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